July 21, 2019


Stem Cell Therapy for Lung Fibrosis and Emphysema-Hope Medical Group

Stem cell treatment for lung fibrosis and emphysema


Lung Fibrosis DiagramFibrosis is a proliferation of fibrous connective tissue.

The process occurs normally in the formation of scar tissue to replace normal tissue lost through injury or infection. It is an abnormal condition in which fibrous tissue spreads over or replaces normal smooth muscle or other normal organ tissue.

Fibrosis is most common in the heart, lung, peritoneum, and kidney.

Pulmonary Fibrosis (also called idiopathic pulmonary fibrosis [IPF], interstitial diffuse pulmonary fibrosis, or fibrosing alveolitis) is an inflammatory lung disorder characterized by abnormal formation of fibrous tissue between the alveoli.

Combined pulmonary fibrosis and emphysema (CPFE) is a recently defined syndrome, in which centrilobular and/or paraseptal emphysemas in upper lung zones coexist with pulmonary fibrosis in lower lobes in individuals. These patients have a characteristic lung function profile, with unexpected subnormal dynamic and static lung volumes, contrasting with a significant reduction of carbon monoxide transfer (DLco) and exercise hypoxemia. Pulmonary hypertension is highly prevalent in CPFE and is the leading determinant of death. Tobacco smoking has been proposed as the main factor in its etiology, though the pathophysiology and its natural history remain to be determined. High-resolution computed axial tomography is the mandatory tool to confirm the diagnosis. Currently, there is no consensus about its treatment since those published to date on this issue are limited to well-characterised series of cases; hence, a better understanding of this entity may help in the development of future therapeutic approaches.

Adult stem cell therapy from umbilical cord derived stem cells have emerged as potential novel approaches for several devastating and otherwise incurable lung diseases, including emphysema, pulmonary fibrosis, pulmonary hypertension, and the acute respiratory distress syndrome.

Treatment Method :

Number of Injection –   2 units of umbilical cord blood stem cell (UCBSC)
2 units of umbilical cord mesenchymal stem cells (UCMSC)

Type of Injection -  Intravenous (IV) Injection x 4
Adjuvant Therapy :

Chinese traditional medicine to recuperate

Treatment Period :

12 days

For more information, please complete a medical form here or visit http://hopestemcell.com/

Free Medical Evaluation





International patients contact:


This email address is being protected from spambots. You need JavaScript enabled to view it.